Eloxx Pharmaceuticals IPO
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel RNA-modulating drug candidates for rare and ultra-rare premature stop codon diseases. The company is expected to uplist or relist its shares, potentially moving to a major exchange like Nasdaq or NYSE.
Key Facts
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | Watertown, MA |
| Funding | Completed stock and pre-funded warrant offering tied to Nasdaq listing (June 2026); specific amount not disclosed |
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics that treat rare genetic diseases caused by nonsense mutations, which create premature stop codons in genetic sequences. These mutations prevent cells from producing full-length, functional proteins, leading to various genetic disorders. Eloxx's lead programs focus on ribosomal modulation to enable cells to read through these premature stop codons.
The company's pipeline includes drug candidates targeting diseases such as cystic fibrosis, Alport syndrome, and other rare genetic conditions. Eloxx's approach represents a potentially transformative treatment strategy for patients with limited therapeutic options, as many rare diseases caused by nonsense mutations currently have no approved disease-modifying therapies.
An uplisting to a major exchange would provide Eloxx with enhanced credibility among institutional investors and potentially easier access to capital needed for advancing its clinical programs. The biotechnology sector often requires substantial funding for research and development, making access to public capital markets critically important for companies like Eloxx.
IPO Status
Eloxx Pharmaceuticals has successfully completed its uplisting to Nasdaq. The company raised capital through a stock and pre-funded warrant offering tied to its Nasdaq listing in June 2026. This represents a successful transition from its previous OTC trading status (ticker: ELOXD) to a major exchange listing. The uplisting to Nasdaq provides Eloxx with improved liquidity, greater visibility among institutional investors, and enhanced access to capital markets for funding its clinical development programs. The company has met Nasdaq's more stringent financial and governance requirements, including minimum share price, market capitalization, and corporate governance standards. The concurrent capital raise through stock and warrant offerings demonstrates investor confidence in the company's prospects following the uplisting.
Competitors
Frequently Asked Questions
Does Eloxx Pharmaceuticals have a stock?
Eloxx Pharmaceuticals has previously been a public company and is now expected to uplist or relist its shares on a major stock exchange. This is not a traditional IPO but rather a move to enhance its public trading status.
When is the Eloxx Pharmaceuticals IPO date?
The specific date for Eloxx Pharmaceuticals' uplisting has not been publicly announced. The timing will depend on meeting exchange requirements and receiving regulatory approval. Sign up for alerts to stay informed.
How can I buy Eloxx Pharmaceuticals stock?
Depending on Eloxx Pharmaceuticals' current trading status, shares may already be available on certain exchanges or over-the-counter markets. Once the uplisting is complete, shares will be more readily accessible through standard brokerage accounts on major exchanges. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts